Cladribina en esclerosis múltiple remitente recidivante de alta actividad

Comisión Nacional de Evaluación de Tecnologías de Salud (CONETEC) (CONETEC).
s.l; CONETEC; jun. 2022.
Não convencional Espanhol | BRISA | ID: biblio-1379687

Documentos relacionados

  1. [Cladribine in the treatment of relapsing multiple sclerosis].
  2. Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis.
  3. Prediction of relapse activity when switching to cladribine for multiple sclerosis.
  4. Double immune reconstitution therapy: Cladribine after alemtuzumab in the treatment of multiple sclerosis.
  5. Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets.
  6. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
  7. Cytokine Secretion Dynamics of Isolated PBMC after Cladribine Exposure in RRMS Patients.
  8. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
  9. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
  10. Cladribina en el tratamiento de la sclerosis múltiple recurrente